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Abstract 
Purpose. A novel chordal system enables automated implantation of artificial mitral chords to treat 
mitral regurgitation (MR). This paper summarizes the “first-in-man” initial clinical results.  
 
Description. The CHAGALL trial is a single arm, multi-center, prospective study to test the 
feasibility of this system for mitral repair.  The interim clinical and echocardiographic results of the 
first 5 patients with a 12 months follow-up are presented.  
 
Evaluation. Five patients (mean age 64 years) with severe MR received implantation of neochords 
with this device under cardiopulmonary bypass. Technical success was obtained in all patients. 
TEE showed either no or trace residual MR (<1+/4+) following repair. Survival at 30 days was 
100% and no device-related complication occurred. Reduction of mitral regurgitation was 
sustained up to 12 months. 
 
Conclusions. This novel chordal system is promising because it greatly facilitates the deployment 
of neochords to repair the mitral valve. Results at 12 months are encouraging. The device is 
currently under development for transcatheter approach.  
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Technology 
 
Surgical repair of the mitral valve (MV) represents an established treatment of severe degenerative 
mitral regurgitation, with superior outcomes over valve replacement (1,2). However, the rates of 
MV repair are highly variable, with less successful repair rates in low-volume centres (3). Different 
techniques allow excellent results in term of efficacy and durability, but largely depend on valve 
anatomy and surgeon preference. Among them, the implantation of e-PTFE neochords has been 
associated with excellent long-term outcome (4-7). Nevertheless, a simple and standardized 
technology allowing a significant increase of valve repair especially in low-volume centres and for 
high-risk patients is welcome. The ChordArt® system (CoreMedic, Radolfzell, Germany) has been 
designed for quick and reliable implantation of artificial mitral chords to treat degenerative MR 
through a standard sternotomy, a less-invasive surgical or even a transcatheter approach.  
Feasibility, safety and efficacy of the ChordArt System are under clinical investigation in the First-
in-Man prospective CHAGALL (CHordArt system study for the treatment of mitral ReGurgitAtion 
due to leaflet proLapse or fLail) trial (NCT03581656).  
 
Technique 
 
The ChordArt is a single-use, hand-held device designed for placing artificial neochords in an 
antegrade way to restore optimal coaptation of a prolabing mitral leaflet. The delivery system is 
designed to deploy the pre-loaded implant in a stepwise mode, advancing the 1.5 mm needle tip 
through the leaflet into the papillary muscle.  
ChordArt® consists of the delivery system (Figure 1) and the Implant (Figure 2). The Implant is pre-
loaded in the system and consists of 3 components: the proximal anchor (for leaflet anchoring), the 
cord (ePTFE suture) and the distal implant (papillary muscle anchor). The distal anchor is a two-
pieces assembly consisting of the crown pressed on the collet. The anchors are made of nickel-
titanium alloys connected with a prefabricated cv5 ePTFE chord (size ranging from 10 to 30 mm 
length in 2 mm steps) that is commonly used as cardiovascular implant.  
The appropriate size is identified using 3D-echocardiography and confirmed by intraoperative 
measurement (Figure 3).  
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Additional informations on the device/implant and operative technique are described in the 
Supplementary file. The target prolapsing segment is identified and grasped with the ChordArt® 
device. After confirmation of stable leaflet grasping, puncture of the leaflet is performed with the 
needle tip of the system. Thereafter, the target papillary muscle is localized and the tip of the 
Chordart® guided towards it. The papillary muscle is punctured at his fibrotic tip and the distal 
anchor delivered (Figure 4). If multiple chordae are required, the steps are repeated. Valve repair 
is completed with annuloplasty or further leaflet repair. Figure 4 shows implantation and Figure 5 
depicts pre- and postoperative echocardiography. 
 
Clinical Experience 
 
This is an interim analysis of the first 5 patients with protocol-specified clinical and 
echocardiographic follow-up conducted at 30-days and 3, 6 and 12 months to support European 
market conformity (CE). The protocol was approved by the national authorities and the ethics 
committee. All patients provided written informed consent.  
Primary safety endpoints are freedom from death and major adverse events (MAE) at 30 days.  
Primary efficacy endpoints are technical success (absence of MAE, successful deployment and 
retrieval of the device, no need for re-intervention until end of the procedure) and device success 
(MR Reduction > 1 grade from baseline assessed at 30 days). The study is conducted according to 
the guidelines of the Mitral Valve Academic Research Consortium (MVARC) as well as 
International Standards Organization (8).  
Serious adverse events (SAEs) were reported and adjudicated by a data safety and monitoring 
committee of independent physicians. Monitoring, collection of data and initial data analysis were 
performed by the sponsor. 
Patients underwent protocol-directed pre-operative trans-oesophageal 2D and 3D 
echocardiography. MR severity was quantified using semi-quantitative and quantitative 
assessment by an independent Core-Lab that also assessed postoperative echocardiography. 
Anatomical feasibility was determined by an independent steering committee. Main exclusion 
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criteria were: commissural lesion, anterior or bileaflet prolapse, functional MR, severe calcification, 
concomitant aortic or tricuspid disease requiring treatment and myocardial revascularisation.  
Five consecutive male patients (range from 47 to 76 years) with severe degenerative MR (STS 
score 0.67% (range 0.31-1.22%) underwent MV repair and received neochords implantation with 
this device. Characteristics are summarized in Table 1.  
Four patients received 2 ChordArt® Implants, while one patient received 1 implant. In one case, 
initial implants were removed and replaced with two longer implants without any complications. 
Single ChordArt® implantation ranged from 1 to 5 min. In all cases the device was successfully 
deployed and the delivery system retrieved as intended to use.  
No intraoperative adverse event was observed. After weaning from CPB, TOE showed no or trace 
residual MR (<1+/4+) in all patients (Figure 5). Discharge echocardiography confirmed these 
results in all patients (Table 2).  
Survival was 100% until 12 months and no patients experienced any MAE. Primary safety 
endpoints were achieved in 5/5 patients (100%). Four adverse events were observed during the 
hospitalisation; atrial fibrillation (n=2), respiratory infection (n=1) and convulsion after extubation 
(n=1). 
At the time of the present report, all patients have reached 1 year follow-up. Echocardiography 
confirmed stable results of the MV repair, with all patients showing no or trace MR (<1+/4+). CT 
scan was performed at 1 month after the procedure and showed proper position of the implant 
(Figure 6). 
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Comment 
This study demonstrates early feasibility of an automated ePTFE neochords implant system. 
Recently, MV repair using neochords has received more attention because of a shift from resection 
to more conservative approach of prolapsing leaflets (“respect instead of resect” strategy) (9). Our 
data show that implantation of ePTFE neochords with the ChordArt® System achieves very 
satisfactory early results comparable to those obtained with neochord loops that we have used 
since many years. In all cases, the lesion was repaired as planned, with no significant residual MR. 
In contrary to other devices (Mitra-Clip, Cardioband) the “foot-print” left by ChordArt® on cardiac 
structures is minimal and allows uncomplicated further repair or replacement. 
The choice of the proper length of a neochord is critical and needs careful assessment of the 
papillary muscle to annulus distance. Pre-operative sizing of the optimal chordal length using 
transesophageal echocardiography has improved the standardization of the techniques even in 
less experienced hands.   
Two different devices have been used so far. The NeoChord is a beating-heart system that uses 
adjustable PTFE sutures through a transapical approach. It enables support of the free edge of the 
leaflets with real-time adjustment of the chordal length. The device obtained CE mark in 2012 and 
has been used in over 600 patients (5-6). The efficacy in reducing MR clearly depends on the 
complexity of the lesion. One-year freedom from composite endpoints was 94% in simple anatomy 
but lower in more complex cases.  
The Harpoon device (Edwards Lifescience, Irvine, USA) has been investigated in an early 
feasibility trial in posterior prolapse (7). It is a 14 Fr device that allows transventricular implantation 
of multiple PTFE chord with subsequent echo-based adjustment of the length. It differs from the 
NeoChord since leaflet anchoring occurs with a preformed knot instead of free-edge leaflet fixation. 
Among 30 patients reported in the initial feasibility trial, three required conversion to mitral surgery. 
At one month, MR was mild or less in 89% (24/27) and moderate in 11% (3/27). At six months, MR 
was mild or less in 85% (22/26), moderate in 8% (2/26), and severe in 8% (2/26).  
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The major difference between ChordArt and these two technologies is the access (left atrium 
versus left ventricle) and the fact that ChordArt is anchored anatomically and not close to the left-
ventricular apex. 
MRI simulations in healthy volunteers have shown that ChordArt neochords anchored into the 
papillary muscles mimick the real anatomy. This approach should be preferred to the left 
ventricular apex, since it is associated with a reduced risk of leaflet tears, residual prolapse and 
incidence of systolic anterior motion (10). 
MV repair with the ChordArt® System is safe, simple and allows effective reduction of MR in the 
short-term. The safety and effectiveness of the ChordArt therapy needs further validation on a 
larger patient population. A fully transcatheter system represent the natural evolution of the 
technique and will be available soon.  
 
Disclosures and Freedom of Investigation 
The authors received no funds for the conduct of this study. The material used for the patients was 
generously donated by Coremedic company to the users.  
 
All authors had complete freedom of investigation as well as full control of the design of the study, 
methods used, outcome parameters, analysis of data, and production of the present written report. 
 
Disclaimer: The Society of Thoracic Surgeons, The Southern Thoracic Surgical Association, and 
The Annals of Thoracic Surgery neither endorse nor discourage the use of the new technology 
described in this article. 
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Figure Legends 
Figure 1. The ChordArt device consists of four major components, the handle, the trigger, the 
shaft and the needle tip. The delivery system is used to advance the needle tip through the valve 
leaflet at the site of the planned leaflet anchoring, down to the papillary muscle.  
 
Figure 2. The ChordArt implant (A) consists of three major components: the proximal implant 
(nitinol pledget for leaflet securement), the chord (ePTFE suture) and the distal implant (papillary 
muscle anchor). The distal implant is a two-piece assembly consisting of the crown pressed on the 
collet. Panel B shows the final aspect of the neo-implanted chord, fixed proximally to the leaflet 
and distally to the papillary muscle. 
 
Figure 3. TEE images showing a pre-procedural mitral valve 3D surgical view highlighting 
posterior leaflet flail (A), a 3D calculation of the expected implant length between posterior leaflet 
and the head of the papillary muscles (B), a post-procedural mitral valve 3D surgical view 
highlighting the leaflet coaptation restoration.  
 
Figure 4. Intraoperative view during implantation of a mitral chord. Proper localization of the site 
on the leaflet (A), punction of the posterior leaflet 3-4 mm from the free edge with the delivery 
device (B) and inspection of the leaflet following retrieving of the delivery device (C) with the 
proximal implant deployed on the leaflet. 
 
Figure 5. Echocardiographic assessment before (A) and after mitral repair using the ChordArt 
system: before discharge (B), at one month (C) and 6 months (D) follow-up.  
 
Figure 6. Computerized Tomography at 1 month follow-up of two implanted ChordArt® systems in 
a reconstructed 2-chamber view showing minimal footprint and proper positioning of the implants 
(A), including the proximal implant anchors (B) and the distal implant anchors (C). 
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Table 1. Pre-operative characteristics of the 5 patients  
 
 
 
Pt 
ID 
Age STS 
score 
(%) 
LVEF 
(%) 
sPAP LV internal 
diameter in 
end systole 
(LVIDs - 
cavity size) 
(mm) 
LV internal 
diameter in 
end 
diastole 
(LVIDd - 
cavity size) 
(mm) 
Additional 
pathologies 
NYHA 
class 
1 59 0.315 55 40,67* 45 65 Paroxysmal AF  II 
2 64 0.477 61 41 38 57 Paroxysmal AF Hypertension II 
3 76 1.223 65 49 41 64 
Hypertension 
Mildly dilated 
aorta (4.4cm) 
II 
4 47 NA 62 40,7* 41 60 - III 
5 68 0.654 55 32 40 61 
History of PCI 
LAD stented in 
2016, RCA 
stented in 
2018) 
Hypertension 
II 
* Estimated value by average imputation 
   NA= Not Available 
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Table 2. Intra-operative data 
 
Pt 
ID 
# of chords used Residual 
MR 
Overall 
procedure 
time (min) 
Time 
of  
Atrial 
Access 
(min) 
Time of 
device  
retrieval 
(min) 
from 
atrium 
(min) 
Time of  
atrium 
closure 
(min) 
Chordae 
Implant time 
(min) 
1st  2nd  3rd  4th  
1 2 None 142 60 35 47  2 3 - - 
2 2 Trace 141 24 60 57 1 5 - - 
3 2 Trace 74 25 27 22  1 2 - - 
4 1 (1 chord, too 
short, removed) None 135 40 70 25 
2 - - - 
5 2 (2 chords 
implanted and 
removed,replaced 
with 2 chords of 
another size) 
Trace 200 70 88 42 
3 1 1 3 
 






